\n
The Senior Vice President, Global Medical Affairs will set all Global Medical Affairs strategies and is accountable for management of all Global Medical Affairs initiatives in support of all Development and Commercial programs. This leader will be responsible for development and strategic oversight of the company’s post-approval activities, building robust Key Opinion Leader partnerships, building and managing a high functioning global medical affairs MD’s, Medical Science Liaisons and Patient Diagnosis teams. The ideal candidate will have extensive experience in global drug development, managing investigator research and supporting long-term disease monitoring/registry programs, KOL development and successful track record in patient community relationships. The role reports to the Chief Medical Officer.
\nRemote: Officially documented as working full-time from home, with travel to Ultragenyx's offices or other locations on occasion as needed.
\nThe typical annual salary range for this full-time position is listed below. This range reflects the characteristics of the job, such as required skills and qualifications and is based on the office location noted in this job posting. The range may also be adjusted based on applicant's geographic location.
\n
This position is eligible for annual bonus and equity incentives. Actual individual pay is determined by demonstrated experience and internal equity alignment.
Ultragenyx Pharmaceutical is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital and veteran status, and any other status or classification protected by applicable federal, state, and/or local laws. Reasonable accommodation will be provided for all protected statuses or classifications protected by applicable law, including individuals with disabilities, disabled veterans, for pregnancy, childbirth, and related medical conditions, and based on sincerely held religious beliefs. Applicants can request an accommodation prior to accepting a job offer. If you require reasonable accommodation in completing this application, or in any part of the recruitment process, you may contact Talent Acquisition by emailing us at talentacquisition@ultragenyx.com.
\nIt is unlawful in Massachusetts to require or administer a lie detector test as a condition of employment or continued employment. An employer who violates this law shall be subject to criminal penalties and civil liability.
\nFull-Time
Confirmed live in the last 24 hours
Develops therapies for rare genetic diseases
$416.8k - $514.8k/yr
Expert
Remote in USA
Get referrals →
You have ways to get a Ultragenyx Pharmaceutical referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 3 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Ultragenyx Pharmaceutical develops therapies for rare and ultra-rare genetic diseases, focusing on conditions with limited treatment options. The company has a diverse pipeline of clinical-stage programs, allowing it to address multiple rare diseases simultaneously. Revenue is generated through the sale of FDA-approved therapies like burosumab and UX007, which validate their scientific approach. Ultragenyx aims to transform research into effective treatments while ensuring a consistent supply of medicines for patients.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Novato, California
Founded
2010
Help us improve and share your feedback! Did you find this helpful?
Paid Vacation
Volunteer Days
Stock Options
Company Equity
Wellness Program
Professional Development Budget
Tuition Reimbursement
Several companies are working on new investigational treatments for Angelman syndrome, a rare genetic disorder that affects the nervous system and causes developmental delays, intellectual disability, seizures and speech impairment. Ionis and Ultragenyx are competing to bring investigational antisense oligonucleotide treatments to the market, while Neuren is betting on a synthetic peptide that can be delivered orally. It’s a tight race in a disease space with a high unmet need.Affecting 500,000 to 1 million patients worldwide, Angelman syndrome has no approved disease-modifying treatments. Although antiseizure medication is available, these drugs do not address the root cause, a genetic mutation in the UBE3A gene on chromosome 15. In Angelman syndrome, only the copy of the UBE3A gene inherited from the mother is functional, while the father’s allele is mutated.Both Ionis and Ultragenyx are currently in Phase III trials with their oligonucleotides, called ION582 and GTX-102, respectively. Meanwhile, Neuren is conducting a mid-stage trial on NNZ-2591, a twice-daily oral solution consisting of a synthetic peptide that modulates acetylcholine neurotransmission.Ionis’ ION582 is an investigational intrathecal injection that targets a long noncoding RNA to increase expression of the UBE3A protein in neurons
Recent Developments In January 2024, Ultragenyx Pharmaceutical Inc. announced that the National Institute for Health and Care Excellence (NICE) has released a final draft guidance recommending Evkeeza (evinacumab) for use within NHS England.
NOVATO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) - Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 10:30 AM PT.
Ultragenyx is developing an antibody treatment for the disease called setrusumab that works by blocking sclerostin, a protein that inhibits bone formation.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company dedicated to developing novel therapies for rare and ultra-rare genetic diseases, with a focus on advancing treatments where there are unmet medical needs.